Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
ATTENTION NASDAQ: REGN INVESTORS: Contact Berger Montague About a Regeneron Pharmaceuticals, Inc. Class Action Lawsuit
03:44pm, Monday, 13'th Jan 2025
PHILADELPHIA , Jan. 13, 2025 /PRNewswire/ -- A securities class action lawsuit has been filed against REGENERON PHARMACEUTICALS, INC. ("Regeneron" or the "Company") (NASDAQ: REGN).
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
12:13pm, Monday, 13'th Jan 2025
NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsu
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal se
Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky
11:15am, Monday, 13'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal se
LOS ANGELES, CA / ACCESSWIRE / January 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc
SAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31, 2024, wipin
Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?
09:26am, Monday, 13'th Jan 2025
REGN's Eylea faces a rapid decline in sales, impacting overall performance even though Dupixent maintains momentum. We advise investors to stay on the sidelines for now.
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal se
NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regenero
Dupixent ® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in which type 2 inflammation plays a role EYLEA HD ® and EY
Primary endpoint of DFS met at first prespecified interim analysis, showing a 68% reduction in the risk of disease recurrence or death in patients with high-risk CSCC after surgery compared to placebo
Truveta sells stakes to Regeneron, Illumina in deal to build genetic database
06:07am, Monday, 13'th Jan 2025
Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals , Illumina and 17 U.S. health systems will take a $320 million stake in the company as part of a deal to build the w
The Truveta collaboration will extend Regeneron Genetics Center's ® (RGC TM ) world-leading DNA sequence-linked healthcare database (now including almost three million de-identified patient volunteer
SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Regeneron business and prospects, resulting in its stock trading at inflated prices.
NEW YORK , Jan. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN dur
